Breast Cancer Research and Treatment

, Volume 65, Issue 2, pp 111–118 | Cite as

p53 Protein Accumulation in Non-Invasive Lesions Surrounding p53 Mutation Positive Invasive Breast Cancers

  • Susan J. Done
  • Nona C.R. Arneson
  • Hilmi Özçelik
  • Mark Redston
  • Irene L. Andrulis
Conference Report


p53 mutation is a common event in sporadic breast cancer being found in 15–50% of invasive carcinomas. The purpose of this study was to determine the earliest histologic stage at which p53 mutation could be detected with a widely used anti-p53 antibody (DO7, Novocastra) which recognizes both wild type and mutant forms. p53 expression was assessed immunohistochemically in 12 primary breast carcinomas with known p53 mutations and in all pre-malignant epithelial lesions surrounding these invasive cancers. Strong p53 nuclear staining was found in all of the tumors known to have missense mutations and none of the tumors with truncation mutations. In cases with intense staining in the invasive carcinoma, a similar quality of staining was also seen in all areas of DCIS (ductal carcinoma in situ) and was representative of missense p53 mutations. Lighter nuclear staining intensity was observed in up to 40% of cells in areas of hyperplasia and in up to 30% of normal breast lobules irrespective of the type of mutation found in the invasive carcinoma. This weak staining was not specific to mutated p53 and may indicate increased amounts of normal p53 protein.

We conclude that p53 inactivation occurs prior to invasion in breast carcinogenesis, with mutations being uniformly identified in DCIS associated with p53-mutated invasive carcinomas. In contrast, there is no evidence that epithelial hyperplasia or epithelial cells of the terminal duct lobular unit harbor the same mutations as their associated invasive carcinoma.

breast cancer DCIS hyperplasia mutation positive cases p53 protein 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39-47, 1994Google Scholar
  2. 2.
    Done SJ, Arneson NC, Ozcelik H, Redston M, Andrulis IL: p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 58: 785-789, 1998Google Scholar
  3. 3.
    Stephen CW, Helminen P, Lane DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 248: 58-78, 1995Google Scholar
  4. 4.
    Umekita Y, Kobayashi K, Saheki T, Yoshida H: Nuclear accumulation of p53 prote in correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn J Cancer Res 85: 825-830, 1994Google Scholar
  5. 5.
    Chakravarty G, Redkar A, Mittra I: A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer 74: 1181-1187, 1996Google Scholar
  6. 6.
    Lohmann D, Ruhri C, Schmitt M, Graeff H, Hofler H: Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 2: 36-41, 1993Google Scholar
  7. 7.
    Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD: Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 5: 187-193, 1996Google Scholar
  8. 8.
    MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36: 71-81, 1995Google Scholar
  9. 9.
    Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: Nuclear accumulation of p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993Google Scholar
  10. 10.
    Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177: 225-232, 1995Google Scholar
  11. 11.
    Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182, 1996Google Scholar
  12. 12.
    Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996Google Scholar
  13. 13.
    Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965, 1993Google Scholar
  14. 14.
    Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, Kovach JS: Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 84: 246-252, 1992Google Scholar
  15. 15.
    Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E: p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59: 5572-5577, 1999Google Scholar
  16. 16.
    O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 71: 67-72, 1994Google Scholar
  17. 17.
    Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29-35, 1996Google Scholar
  18. 18.
    Sasa M, Kondo K, Komaki K, Morimoto T, Monden Y: p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer. J Surg Oncol 56: 46-50, 1994Google Scholar
  19. 19.
    Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, Ballard D, Conway K, Liu ET: p53 mutations in benign breast tissue. J Clin Oncol 13: 2293-2300, 1995Google Scholar
  20. 20.
    Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, Laucirica R: p53 accumulation in benign breast biopsy specimens. Hum Pathol 26: 155-158, 1995Google Scholar
  21. 21.
    Fischler DF, Sebek BA, Tubbs RR, Biscotti CV: p53 expression in intraductal epithelial hyperplasia, atypical intraductal hyperplasia, and intraductal carcinoma of the breast [letter; comment]. Histopathology 28: 93-94, 1996Google Scholar
  22. 22.
    Rohan TE, Hartwick W, Miller AB, Kandel RA: Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk [see comments]. J Natl Cancer Inst 90: 1262-1269, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Susan J. Done
    • 1
    • 2
  • Nona C.R. Arneson
    • 2
  • Hilmi Özçelik
    • 1
    • 2
  • Mark Redston
    • 1
    • 2
  • Irene L. Andrulis
    • 1
    • 3
    • 2
  1. 1.Departments of Laboratory Medicine and PathobiologyMount Sinai Hospital, The University of TorontoTorontoCanada
  2. 2.Samuel Lunenfeld Research InstituteMount Sinai Hospital, The University of TorontoTorontoCanada
  3. 3.Department of Molecular and Medical GeneticsMount Sinai Hospital, The University of TorontoTorontoCanada

Personalised recommendations